PT1831369E - Inibição de arni de amilóide a sérica para o tratamento de glaucoma - Google Patents

Inibição de arni de amilóide a sérica para o tratamento de glaucoma Download PDF

Info

Publication number
PT1831369E
PT1831369E PT58550609T PT05855060T PT1831369E PT 1831369 E PT1831369 E PT 1831369E PT 58550609 T PT58550609 T PT 58550609T PT 05855060 T PT05855060 T PT 05855060T PT 1831369 E PT1831369 E PT 1831369E
Authority
PT
Portugal
Prior art keywords
glaucoma
treatment
serum amyloid
rnai inhibition
rnai
Prior art date
Application number
PT58550609T
Other languages
English (en)
Inventor
Abbot F Clark
Wan-Heng Wang
Loretta Mcnatt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1831369E publication Critical patent/PT1831369E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
PT58550609T 2004-12-23 2005-12-19 Inibição de arni de amilóide a sérica para o tratamento de glaucoma PT1831369E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63870604P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
PT1831369E true PT1831369E (pt) 2012-12-06

Family

ID=36440864

Family Applications (1)

Application Number Title Priority Date Filing Date
PT58550609T PT1831369E (pt) 2004-12-23 2005-12-19 Inibição de arni de amilóide a sérica para o tratamento de glaucoma

Country Status (18)

Country Link
US (7) US20060172961A1 (pt)
EP (1) EP1831369B1 (pt)
JP (3) JP2008525469A (pt)
KR (1) KR101311275B1 (pt)
CN (2) CN102172407A (pt)
AR (1) AR051848A1 (pt)
AU (1) AU2005322228B2 (pt)
BR (1) BRPI0516378A (pt)
CA (1) CA2591403A1 (pt)
DK (1) DK1831369T3 (pt)
ES (1) ES2393325T3 (pt)
MX (1) MX2007007388A (pt)
PL (1) PL1831369T3 (pt)
PT (1) PT1831369E (pt)
SI (1) SI1831369T1 (pt)
TW (1) TWI401316B (pt)
WO (1) WO2006071691A2 (pt)
ZA (1) ZA200704936B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609206A2 (pt) 2005-03-11 2010-03-02 Alcon Inc inibiÇço mediada por rnai de proteÍna relacionada frizzled-1 para tratamento de glaucoma
AU2008308784B2 (en) * 2007-10-01 2013-07-18 Arrowhead Research Corporation Self complementary AAV-mediated delivery of interfering RNA molecules to treat or prevent ocular disorders
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
TW200930405A (en) * 2007-11-15 2009-07-16 Alcon Res Ltd Low density lipoprotein receptor-mediated siRNA delivery
AR069704A1 (es) 2007-12-18 2010-02-10 Alcon Res Ltd Sistema de administracion de rnai de interferencia y usos del mismo
WO2010036962A1 (en) 2008-09-25 2010-04-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
US20130178421A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
JP6671363B2 (ja) 2014-07-15 2020-03-25 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド Ｃｄ４４の単離されたポリペプチドおよびその使用
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CN1196797C (zh) * 2000-02-29 2005-04-13 阿尔康公司 青光眼的诊断和治疗药物
AU2001245793A1 (en) * 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
IL151928A0 (en) * 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
US6455308B1 (en) * 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
WO2003062792A2 (en) * 2002-01-22 2003-07-31 Trustees Of The University Of Pennsylvania Methods for determining drug responsiveness
NZ546806A (en) * 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
EP1504126B1 (en) * 2002-05-03 2014-02-26 Duke University A method of regulating gene expression
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US8729036B2 (en) * 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
EP1534832A2 (en) * 2002-09-04 2005-06-01 Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Compositions and methods for tissue specific or inducible inhibition of gene expression
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
US7718697B2 (en) * 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US20050137122A1 (en) * 2003-12-17 2005-06-23 Alcon, Inc. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease

Also Published As

Publication number Publication date
EP1831369B1 (en) 2012-09-19
AU2005322228A1 (en) 2006-07-06
ZA200704936B (en) 2008-10-29
SI1831369T1 (sl) 2013-01-31
AR051848A1 (es) 2007-02-14
WO2006071691A8 (en) 2006-10-19
JP2012193209A (ja) 2012-10-11
BRPI0516378A (pt) 2008-09-02
AU2005322228B2 (en) 2011-08-11
ES2393325T3 (es) 2012-12-20
TWI401316B (zh) 2013-07-11
PL1831369T3 (pl) 2013-07-31
US20110054008A1 (en) 2011-03-03
JP2015044858A (ja) 2015-03-12
US20120122961A1 (en) 2012-05-17
CN101124322A (zh) 2008-02-13
KR101311275B1 (ko) 2013-09-27
JP2008525469A (ja) 2008-07-17
US20150225720A1 (en) 2015-08-13
CN101124322B (zh) 2011-12-14
US20100152279A1 (en) 2010-06-17
TW200634153A (en) 2006-10-01
KR20070093118A (ko) 2007-09-17
WO2006071691A3 (en) 2006-11-16
DK1831369T3 (da) 2012-10-08
US20130123337A1 (en) 2013-05-16
EP1831369A2 (en) 2007-09-12
MX2007007388A (es) 2007-08-23
CA2591403A1 (en) 2006-07-06
US20060172961A1 (en) 2006-08-03
US20140357692A1 (en) 2014-12-04
WO2006071691A2 (en) 2006-07-06
CN102172407A (zh) 2011-09-07

Similar Documents

Publication Publication Date Title
ZA200704936B (en) Rnai Inhibition of serum amyloid a for treatment of glaucoma
ZA200704932B (en) Rnai inhibition of CTGF for treatment of ocular disorders
EP1755584A4 (en) TREATMENT OF MYOPIA
SI1802334T1 (sl) Postopek za zdravljenje intraokularnih neovaskularnih bolezni
EP1711510A4 (en) THERAPY WITH RNAI AGENTS APPLIED IN THE TREATMENT OF OCULAR DISEASES RESULTING FROM NEOVASCULARIZATION
EP1766091A4 (en) BIOMARKER FOR MONITORING THE INHIBITION OF THE IMPDH PATH
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
HUE062491T2 (hu) A myopa progressziójának korlátozására szolgáló eszközök
EP1749532A4 (en) MEDICAMENT FOR HEALING OR TREATMENT OF INJURY
IL184184A0 (en) Process for the purification of duloxetine hydrochloride
ZA200705297B (en) Methods and compositions for treating amyloid related diseases
EP1754485A4 (en) MEANS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
IL175517A0 (en) Processes for preparation of ziprasidone
PL381702A1 (pl) Sposób wytwarzania timosaponiny BII
IL180707A0 (en) Polymorphs of atomoxetine hydrochloride
EP2026822A4 (en) TOPICAL TREATMENT FOR EYE SURGERY DISEASES
IL175695A0 (en) Process for the preparation of valacyclovir hydrochloride
IL188787A (en) Preparations for the treatment of diabetic eye complications
ZA200806489B (en) A method for determining the effectiveness of a treatment for preeclampsia
EP1734957A4 (en) THIAZOLE SULFAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP1771203A4 (en) INHIBITION OF NF-KB
EP1718294A4 (en) METHODS OF TREATING COMPLICATIONS OF DIABETES
ZA200706083B (en) RNAI-mediated inhibition of ocular targets
HK1117873A1 (en) Rnai-mediated inhibition of igf-1r for treatment of ocular angiogenesis
PL2026801T3 (pl) Deferazyroks do leczenia dziedzicznej hemochromatozy